Clinical trial
HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.
NCT00378976 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00378976 |
|---|---|
| Title | HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men. |
| Official title | A Randomized, Double-blind, Placebo-controlled Crossover Trial of Valacyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Men Who Have Sex With Men (MSM). |
| Lead sponsor | University of Washington, Other |
| Collaborators | GlaxoSmithKline Industry Asociación Civil Impacta Salud y Educación, Peru |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infection, Herpes Simplex, Sexually Transmitted Diseases |
| Intervention type | Drug |
| Interventions | valacyclovir, matching placebo |
| Enrollment | 20 |
| Start date | Aug 1, 2003 |
| Completion | Jul 1, 2004 |
| First posted | Sep 21, 2006 |
| Last update posted | Aug 22, 2013 |
| Countries | Peru |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: